Sildenafil Treatment of Primary Pulmonary Hypertension
| dc.contributor.author | Laupland, Kevin B | |
| dc.contributor.author | Helmersen, Doug | |
| dc.contributor.author | Zygun, David A | |
| dc.contributor.author | Viner, Sidney M | |
| dc.date.accessioned | 2018-09-27T12:23:31Z | |
| dc.date.available | 2018-09-27T12:23:31Z | |
| dc.date.issued | 2003-01-01 | |
| dc.date.updated | 2018-09-27T12:23:31Z | |
| dc.description.abstract | A 37-year-old woman with primary pulmonary hypertension and worsening symptomatology underwent pulmonary artery (PA) catheterization and vasodilator trials. Oxygen had no effect, but 10 parts/million of nitric oxide reduced mean PA (PAm) pressure by 20%. Prostacyclin infusion at 8 ng/kg/min decreased the PAm pressure by 11%, but further dose increases were limited by systemic hypotension. Sildenafil in doses of 25 mg or higher resulted in an average decrease of 14% in PAm pressure. Sildenafil is a potentially useful treatment option for patients with primary pulmonary hypertension, and further investigation is warranted. | |
| dc.description.version | Peer Reviewed | |
| dc.identifier.citation | Kevin B Laupland, Doug Helmersen, David A Zygun, and Sidney M Viner, “Sildenafil Treatment of Primary Pulmonary Hypertension,” Canadian Respiratory Journal, vol. 10, no. 1, pp. 48-50, 2003. doi:10.1155/2003/612905 | |
| dc.identifier.doi | https://doi.org/10.1155/2003/612905 | |
| dc.identifier.uri | http://hdl.handle.net/1880/108595 | |
| dc.identifier.uri | https://doi.org/10.11575/PRISM/45197 | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | |
| dc.title | Sildenafil Treatment of Primary Pulmonary Hypertension | |
| dc.type | Journal Article |